Pfizer (NYSE:PFE) reports strong Q3 2026, full-year outlook slightly exceeds expectations
Pfizer (NYSE:PFE) reports strong Q3 2026, full-year outlook slightly exceeds expectations StockStory
Covered in this story
Analyst targets on Pfizer
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 28 Apr 2017.
Summary aggregated from StockStory's public RSS feed. The full reporting belongs to StockStory — please read it on their site.